Bioibérica presents the latest scientific evidence on osteoarthritis at the European Congress of Rheumatology (EULAR 2016)
Symposium on Friday, June 10, 2016 at 08:15
The company, with more than 40 years of experience in osteoarthritis and joint health, presents a symposium with top-level specialists about the new scientific evidence available on the treatment of osteoarthritis.
Program:
Overall treatment effect and contextual effect of osteoarthritis treatments: meta-analysis of randomized clinical trials
Weiya Zhang, BM, MPH, PhD (Nottingham, UK)
Drug use and risk of comorbidities in osteoarthritis
Philip Conaghan, MB BS, PhD, FRACP, FRCP (Leeds, UK)
Chondroitin sulphate for hand osteoarthritis: a randomized, placebo-controlled trial in primary care: the FACTUAL study
George Peat, PhD, MCSP (Keele, UK)
MOSAIC: 24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulphate
Jean-Pierre Pelletier, MD (Montreal, Quebec, Canada)
Long-term effects of treatment on the progression of structural changes in knee osteoarthritis: new follow-up data from the Osteoarthritis Initiative cohort
Johanne Martel-Pelletier, PhD (Montreal, Quebec, Canada)
Long term use of analgesics and risk of osteoarthritis progression and knee replacement from the Osteoarthritis Initiative cohort.
Ali Guermazi, MD, PhD (Boston, MA, USA)
Related News
With World Digestive Health Day around, shortly followed by World Allergy Awareness Week (5-11 June), we’re exploring the increasing relevance of a relatively unknown digestive health disorder – histamine intolerance.
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Bioiberica unveils DAOgest and Dermial® for the first time at Vitafoods 2022.